Identification of NINJ1 as a novel prognostic predictor for retroperitoneal liposarcoma
View abstract on PubMed
Summary
This summary is machine-generated.NINJ1 is a novel prognostic biomarker for retroperitoneal liposarcoma (RPLS). Higher NINJ1 expression correlates with improved overall survival (OS) and disease-free survival (DFS) in RPLS patients, aiding treatment and drug development.
Area Of Science
- Oncology
- Genomics
- Biomarker Discovery
Background
- Retroperitoneal liposarcoma (RPLS) is characterized by frequent local recurrence and poor survival.
- Identifying reliable prognostic biomarkers is crucial for improving patient outcomes.
Purpose Of The Study
- To identify a specific and credible prognostic biomarker for RPLS.
- To validate the prognostic significance of potential biomarkers in independent cohorts.
Main Methods
- Weighted gene co-expression network analysis (WGCNA) was used to construct co-expression modules from TCGA sarcoma dataset.
- Hub genes within significant modules were analyzed for survival association using Kaplan-Meier and Cox regression.
- External validation was performed on a Chinese RPLS cohort from the RESAR study.
Main Results
- The green co-expression module positively correlated with overall survival (OS) and disease-free survival (DFS).
- NINJ1, a hub gene in the green module, showed a positive association with OS in the TCGA cohort.
- Elevated NINJ1 expression was linked to higher OS and DFS in both training and validation cohorts, confirmed by multivariable analysis.
Conclusions
- NINJ1 emerges as a significant independent prognostic biomarker for RPLS.
- This finding supports NINJ1's potential role in clinical treatment decisions and targeted therapy development for RPLS.

